AI-enabled biotech startup analysis

Designing a Phase 3 in HS

High-level design of a potential Phase 3 trial in hidradenitis suppurativa

Designing a Phase 3 in CSU

High-level design of a potential Phase 3 trial in chronic spontaneous urticaria

Contineum Therapeutics

Latest raise: Filed for IPO, March 2024

Stage: Phase 2

Indications: Immunology and inflammation

Modality: Small molecule

Alumis

Latest raise: $259M Series C, March 2024

Stage: Phase 2

Indications: Immunology

Modality: Small molecule

Sionna Therapeutics

Latest raise: $182M Series C, March 2024

Stage: Phase 1

Indications: Cystic Fibrosis

Modality: Small molecule

Boundless Bio

Latest raise: Filed for IPO, March 2024

Stage: Phase 2

Indications: Oncology

Modality: Small molecule

Viking Phase 2 obesity

Comparing Viking's GLP-1 data to Novo's oral GLP-1 data

Ironwood Phase 3 SBS

Analyzing Ironwood's Phase 3 in short bowel syndrome

Boehringer / Zealand Phase 2 MASH

Analyzing Boehringer / Zealand Pharma's Phase 2 in MASH

Janux Phase 1 results

Analyzing Janux's Phase 1 data in solid tumors

Palatin Phase 3 results

Analyzing Palatin's Phase 3 data in dry eye disease

EyeBio Phase 1/2 results

Analyzing EyeBio's Phase 1/2 results in diabetic macular edema and wet AMD

Profound Bio

Latest raise: Series B, February 2024

Stage: Phase 2

Indications: Oncology

Modality: Antibody-drug conjugate

Neurona Therapeutics

Latest raise: Late stage private round, February 2024

Stage: Phase 2

Indications: Neurological disease

Modality: Cell therapy

Accent Therapeutics

Latest raise: Series C, February 2024

Stage: Preclinical

Indications: Oncology

Modality: Small molecule

LB Pharmaceuticals

Latest raise: Series C, February 2024

Stage: Phase 2

Indications: Psychiatry

Modality: Small molecule

Basking Biosciences

Latest raise: Private financing, February 2024

Stage: Phase 2

Indications: Cardiovascular disease

Modality: Aptamer

Invea Therapeutics

Latest raise: Filed for IPO, January 2024

Stage: Phase 1

Indications: Immunological disease, Inflammatory disease

Modality: Small molecules

Fractyl Health

Latest raise: Filed for IPO, January 2024

Stage: Phase 3

Indications: Obesity, Diabetes

Modality: Device, Gene therapy

Kyverna Therapeutics

Latest raise: Filed for IPO, January 2024

Stage: Phase 2

Indications: Autoimmune disease

Modality: Cell therapy

Alto Neuroscience

Latest raise: Filed for IPO, January 2024

Stage: Phase 2

Indications: Psychiatry, Neurology

Modality: Small molecules

Vico Therapeutics

Latest raise: $60M Series B, January 2024

Stage: Phase 2

Indications: Rare disease, Neurology

Modality: Antisense oligonucleotides

OnCusp Therapeutics

Latest raise: $100M Series A, January 2024

Stage: Preclinical

Indications: Oncology, Hematology

Modality: Antibody-drug conjugates, Monoclonal antibody

HI-Bio

Latest raise: $95M Series B, January 2024

Stage: Phase 2

Indications: Renal disease, Autoimmune disease

Modality: Monoclonal antibody

Metagenomi Technologies

Latest raise: Filed for IPO, January 2024

Stage: Preclinical

Indications: Hematology, Cardiovascular disease, Rare disease, Autoimmune disease

Modality: Gene editing, Cell therapy

ArriVent Biopharma

Latest raise: Filed for IPO, January 2024

Stage: Phase 3

Indications: Oncology

Modality: Small molecules

CG Oncology

Latest raise: Filed for IPO, January 2024

Stage: Phase 3

Indications: Oncology

Modality: Viral therapy

Tome Biosciences

Latest raise: $213M Series A + B, Dec 2023

Stage: Preclinical

Indications: Liver disease, Rare disease, Autoimmune disease

Modality: Gene editing

Carmot Therapeutics

Latest raise: Acquired by Roche for $2.7B upfront, November 2023

Stage: Phase 2

Indications: Obesity, Diabetes

Modality: Peptides, Small molecules

Odyssey Therapeutics

Latest raise: $101M Series C, Dec 2023

Stage: Preclinical

Indications: Inflammatory disease, Autoimmune disease, Cancer

Modality: Small molecules, Antibodies

Seismic Therapeutics

Latest raise: $121M Series B, Dec 2023

Stage: Preclinical

Indications: Autoimmune

Modality: Protease, Bispecific antibody

MBrace Therapeutics

Latest raise: $85M Series B, Nov 2023

Stage: Phase 1

Indications: Solid tumors

Modality: ADC

Kynexis Therapeutics

Latest raise: $57M Series A, Nov 2023

Stage: Preclinical

Indications: Cognitive Impairment Associated With Schizophrenia

Modality: Small molecule

EyeBio

Latest raise: $130M Series A, Nov 2023

Stage: Phase 1/2

Indications: DME, Wet AMD

Modality: Tri-specific antibody

CARGO Therapeutics

Latest raise: $281M IPO, Nov 2023

Stage: Phase 2

Indications: Large B-cell lymphoma, Pediatric acute lymphoblastic leukemia, B-cell malignancies

Modality: CAR-T

OrsoBio

Latest raise: $60M Series A, Nov 2023

Stage: Phase 2

Indications: Type 2 Diabetes, Obesity, Severe dyslipidemias, Lipodystrophies, Organ failure

Modality: Small molecules

Gate Bioscience

Latest raise: $60M Series A, Nov 2023

Stage: Discovery

Indications: N/A

Modality: Small molecules

MapLight Therapeutics

Latest raise: $225M Series C, Oct 2023

Stage: Phase 2

Indications: Schizophrenia, Autism, Alzheimer's disease psychosis, dyskinesias

Modality: Small molecules

Function Oncology

Latest raise: $28M Series A, April 2023

Stage: Discovery

Indications: Oncology

Modality: N/A

Triveni Bio

Latest raise: $92M Series A, Oct 2023

Stage: Preclinical

Indications: Atopic dermatitis

Modality: Monoclonal antibodies

Aiolos Bio

Latest raise: $245M Series A, Oct 2023

Stage: Phase 2

Indications: Asthma, COPD, CSU

Modality: Monoclonal antibodies

Agomab Therapeutics

Latest raise: $100M Series C, Oct 2023

Stage: Phase 2

Indications: Fibrostenosing Crohn's disease, IPF, fibrosis

Modality: Small molecules, Monoclonal antibodies

Neumora Therapeutics

Latest raise: $250M IPO, Sept 2023

Stage: Phase 3

Indications: Depression, Bipolar depression, Alzheimer's disease, Schizophrenia, Parkinson's disease

Modality: Small molecules

Rampart Bio

Latest raise: $85M Series A, Oct 2023

Stage: Preclinical

Indications: Hypophosphatasia

Modality: Gene therapy

MinervaX

Latest raise: $57M, Oct 2023

Stage: Phase 2

Indications: Group B streptococcal vaccine

Modality: Vaccine

AstronauTx

Latest raise: $61M Series A, Oct 2023

Stage: Discovery

Indications: Alzheimer's disease

Modality: Undisclosed

Amplifier Therapeutics

Latest raise: $33M Series A, Oct 2023

Stage: Phase 1

Indications: Cardiometabolic diseases

Modality: Small molecule